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Abstract
Objective: The aim of this prospective study was to
compare serum and urine concentrations of progester-
one-induced blocking factor (PIBF) and serum concen-
trations of anti-inflammatory (IL10) and pro-inflammatory
(IL6, TNFa, IFNg) cytokines of women with threatened
spontaneous abortion with normal pregnancy and to
evaluate the impact of PIBF on outcome of pregnancy.
Methods: A sample of 30 women with threatened spon-
taneous abortion (study group) and 20 healthy pregnant
women (control group) between 6th and 24th gestational
weeks was studied. Serum and urine PIBF, IL10 and IL6,
TNFa, IFNg cytokine concentrations were measured by
enzyme-linked immunosorbent assay (ELISA).
Results: Five (16.7%) pregnancies in the study group
ended missed abortion vs. none in the control group
(P-0.05). Five (20%) threatened aborters delivered
between 24th and 37th weeks of gestation, whereas two
(10%) preterm deliveries occurred in the controls
(P)0.05). PIBF concentrations in urine (19.5"12.9
ng/mL) and serum (214.4"120.6 of patients with threat-
ened abortion were significantly lower than in healthy
pregnant women (45.3"33.7 ng/mL and 357.3"
159.9 ng/mL, respectively). Women with threatened
abortion had significantly lower serum levels of anti-
inflammatory cytokine, but levels of proinflammatory
cytokines were higher in this group compared with
healthy controls.
Conclusions: Determination of progesteron-induced
blocking factor level in body fluids in early pregnancy
might be used for the diagnosis and prognosis of threat-
ened abortion.
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Introduction
Pregnancy can be compromised by a number of
complications such as threatened abortion, recurrent
spontaneous miscarriage, and preterm delivery w20x.
Spontaneous abortion is a common problem affecting
15–20% of all recognized pregnancies. Spontaneous
miscarriages have a range of possible causes including
genetic, anatomical, endocrine, immune, infective,
thrombophilic, and unexplained w13x. A substantial part
of unexplained spontaneous abortion might be attri-
butable to a deleterious immune response of a mother
toward the fetus. A growing body of evidence suggests
that progesterone might play a role in establishing an
adequate immune environment during the early stages of
pregnancy w12, 25x. Particularly interesting are the effects
of pro-inflammatory and anti-inflammatory cytokines on
the conceptus and thus, on the success or failure of
pregnancy w20x. In the presence of progesterone, lym-
phocytes of pregnant women release a protein named
the progesterone-induced blocking factor (PIBF) w26x
which mediates the immunomodulatory and anti-abortive
effects of progesterone w28, 30, 31x. Immunologic
recognition of pregnancy and subsequent activation of
maternal immune system results in an upregulation of
progesterone receptors on activated lymphocytes among
placental cells and CD8q cells. In the presence of suf-
ficient progesterone levels, these cells synthesize PIBF
w32x. Patients at risk of spontaneous abortion have
increased pro-inflammatory and low PIBF and IL-10
expressions on lymphocytes w35x. PIBF alters the profile
of cytokine secretion of activated lymphocytes shifting
the balance toward Th2 dominance w33x. During normal
uneventful pregnancy the concentration of PIBF conti-
nuously increased from the 6th to the 37th gestational
week. After the 41st week, PIBF concentrations dramatic-
ally decrease. In patients with threatened spontaneous
abortion PIBF levels failed to increase during pregnancy
w19x. Therapeutic regimens to prevent spontaneous abor-
tion are limited in efficacy. Still, there is a considerable
controversy about the use of progestogens for the treat-
ment of threatened spontaneous abortion. There are four
main approaches towards progestogen therapy: 1. Do
nothing; 2. No routine therapy, but once or twice weekly
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measurements of progesterone levels to suggest whether
support with progestogens is or is not necessary (the
cut-off level is 300 nmol/L); 3. Routine pharmacological
‘‘support of the pregnancy’’. This is frequently advocated
empirically in all pregnancies following recurrent losses
because ‘‘it can do no harm’’. In our view, this is an unac-
ceptable argument which has no place in ethical treat-
ment regimens; 4. Treat only within properly designed
prospective trials (with adequate follow-up). This is our
preferred option w6x.
The aim of this prospective study was to compare
serum and urine concentrations of PIBF and serum con-
centrations of anti-inflammatory (IL10) and pro-inflam-
matory (IL6, TNFa, IFNg) cytokines of women with
threatened spontaneous abortion with normal pregnancy
and to evaluate impact of PIBF on outcome of pregnancy
as well as the possible underlying mechanisms.
Patients and methods
A prospective study was performed at the Clinics for Gyneco-
logy and Obstetrics, University-Clinical Center Tuzla and Coun-
seling for pregnant women at the department for health
protection of women at the Public Medical Center Tuzla. A study
and control group of pregnant women were formed, as a con-
secutive sample, with a total of 50 examinations. Pregnant
women aged 18–35 years, who had no risk factors for sponta-
neous abortion, were included in this research. The study group
consisted of 30 pregnant women, who were hospitalized at the
Department of Pathology of Pregnancy (Clinics for Gynecology
and Obstetrics in Tuzla), but only those who were hospitalized
due to threatened spontaneous abortion (between 6th and 24th
weeks’ gestation). Threatened spontaneous abortion was
defined as bleeding, spotting and uterine cramps. A gestational
age was determined in all patients by ultrasound examination.
Exclusion criteria were: chronic diseases, e.g., hypertension,
diabetes, renal or cardiac diseases, uncertain gestational age,
previous spontaneous abortion, history of urinary infections in
actual pregnancy, history of pregnancy loss, uterine anomalies
and previous cesarean section. Only singleton pregnancies qual-
ified for the study. The control group consisted of 20 healthy
pregnant women from 6th to 24th gestation weeks who had no
risk factors for spontaneous abortion and who underwent
regular gynecological examinations. Serum and urine samples
were collected from all subjects and PIBF concentration was
measured by enzyme-linked immunosorbent assay (ELISA) w19x.
The analysis was conducted at the Department of Microbiology
and Immunology at Medical Faculty, University of Pecs,
Hungary.
PIBF determination
Briefly, during overnight incubation at 48C, 96-well microtiter
plates were coated either with ani-human recombinant PIBF IgG
(100 mL/well of 2 mg/mL) in 50 mm carbonate buffer pH 9.6
(plate 1), or with human recombinant PIBF (100 mL of 0.5
mg/mL) in 0.5 m Tris buffer pH 6.5 (plate 2). For generating a
standard curve, recombinat PIBF (1000–0.1 ng/mL) in logarith-
mic dilutions in 0.5 m phosphate buffer (pH 7.3–7.4) was incu-
bated with a standard amount of biotin-labeled anti-recombinant
PIBF IgG (400 ng) for 60 min at 378C. Serum and urine samples
were diluted 1/2.5 and 1/5 and incubated with 400 ng biotin-
labeled anti-recombinant PIBF IgG in 0.5 m phosphate-buffered
saline (PBS) for 60 min at 378C before being added to ELISA
plate 1. During the 1 h incubation at 378C, non-specific binding
sites on plate 2 (coated with human recombinant PIBF) were
blocked with 200 mL of 0.1% bovine serum albumin (BSA), 0.5%
gelatin in PBS-Tween. After this incubation step, 100 mL stan-
dard solutions of the serum and urine samples were transferred
from plate 1 to plate 2 and incubated for 1 h at 378C. After
washing the plates three times with PBS-Tween, 100 mL of
1:1000 diluted horseradish peroxidase (HRPO)-conjugated
streptavidine (AP Hungary Ltd, Budapest, Hungary) in 0.1% BSA
PBS-Tween was added and plates were incubated for 30 min at
378C. The reaction was developed by adding the substrate
orthophenylene-diamine (OPD; Sigma, Budapest, Hungary) and
measured at 495 nm.
The concentrations of IL10, IL6, TNFa, IFNg were taken from
blood samples and were measured manually with a quantitative
sandwich enzyme immunoassay (ELISA) after freezing at –708C,
centrifugation and aliquation at the Department of Immunology
and Microbiology in Tuzla. Cytokine concentrations were meas-
ured in serum manually with a high sensitive quantitative sand-
wich enzyme immunoassay (R&D Systems Inc., Minneapolis,
USA). The minimum detectable concentrations of human pro-
inflammatory and anti-inflammatory cytokines were as follows:
IL10 – 3.9 pg/mL, IL6 – 0.7 pg/mL, IFNg – 8 pg/mL and TNF-
a – 1.6 pg/mL. The intra- and inter-assay precision of the all
cytokine assays were -10%. In the serum of pregnant women
from the examined and control group values of IL6, IFNg, TNFa,
IL10 were determined, and the analysis was conducted at the
Department of Microbiology and Immunology, University Clinical
Center Tuzla.
The study was approved by the Ethical Committee of the Uni-
versity Clinical Center Tuzla, Bosnia and Herzegovina (Decision
No. 01/1-37-4-898/07). Every patient was provided with a
written consent for participation.
SPSS V.11.5 software (SPSS Inc, Chicago, Illinois, USA),
Arcus Quick Stat and Microsoft Excel XP Professional were used
for statistical analysis of the study. Student’s t-test was used to
compare the mean values. The distribution of qualitative
variables was compared by x2 or by Fisher’s exact tests. A value
of two-sided P-0.05 was considered significant.
Results
Fifty patients were included in this study, without differ-
ence between clinical characteristics in women with pre-
term delivery and healthy pregnant controls in maternal
age or gestational age at the time of enrollment. The
mean gestational age at the time of blood sampling was
also not different. Active smoking was declared by 20%
in both groups (Table 1).
Five (16.7%) pregnancies with threatened abortion
ended in missed abortion. No missed abortion was regis-
tered in the control group (difference was statistically sig-
nificant). Five (20%) women with threatened abortion
delivered between 24th and 37th weeks’ gestation, where-
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Table 1 Comparison of selected maternal characteristics in women with threatened spontaneous abortion and healthy pregnant
controls.
Threatened abortion Healthy controls P-value
(ns30) (ns20)
Maternal age (years)
Mean"SD 25.3"4.4 24.5"3.7 NS
BMI* (kg/m2)
Mean"SD 24.7"3.7 25.0"3.9 NS
Gestational age at blood sampling
Mean"SD 11.4"3.8 13.3"4.8 NS
Nulliparity (n%) 21 70.0 13 65.0 NS
Smoking (n%) 6 20.0 4 20.0 NS
Educational level (with secondary education; n%) 15 50.0 8 40.0 NS
*BMIsbody mass index.
Table 2 Pregnancy outcome in study and control group.
Threatened Healthy P-value
abortion controls
(ns30) (ns20)
Missed abortion (n%) 5 16.7 – – P-0.05
Preterm delivery (n%) 5 20.0 2 10.0 NS
Table 4 Serum concentrations of anti-inflammatory (IL10) and proinflammatory (IL6, TNFa, IFNg) cytokines.
Threatened abortion Healthy controls P-value
Mean"SD Mean"SD
IL10 serum (pg/mL) 6.7"4.7 7.9"4.9 -0.05
IL6 serum (pg/mL) 3.7"1.4 1.3"1.0 -0.05
TNFa serum (pg/mL) 8.4"3.4 6.7"0.6 -0.05
IFNg serum (pg/mL) 9.6"1.8 7.6"2.6 -0.05
ILsinterleukin, TNFstumor necrosis factor, IFNsinterferon.
Table 3 Progesterone-induced blocking factor (PIBF) serum and urine concentrations of patients with threatened abortion and
healthy pregnant women.
PIBF* (ng/mL) Threatened abortion Healthy controls P-value
Mean"SD Mean"SD
Urine 19.5"12.9 45.3"33.7 -0.05
Serum 214.4"120.6 357.3"159.9 -0.05
*PIBFsProgesterone-induced blocking factor.
as two (10%) with preterm delivery were registered in the
control group. There was no significant difference in pre-
term deliveries between the study and control group
(Table 2).
PIBF concentrations in urine (19.5"12.9 ng/mL) and
serum (214.4"120.6) samples of patients showing clini-
cal symptoms of threatened abortion were significantly
lower than in those of healthy pregnant women
(45.3"33.7 ng/mL; 357.3"159.9 ng/mL, Table 3) Using
a cut-off level of 20.7 ng/mL, PIBF urine concentrations
predicted pregnancy termination with sensitivity 63%,
specificity 90%, positive predictive value 91%, and neg-
ative predictive value 90%, whereas a cut-off level of
182.8 ng/mL PIBF serum concentrations predicted preg-
nancy termination with sensitivity 53%, specificity 95%,
positive predictive value 94%, and negative predictive
value 95%.
Women with symptoms of threatened spontaneous
abortion had significantly lower serum levels of anti-
inflammatory cytokine (IL10), but levels of proinflamma-
tory (IL6, TNFa, IFNg) cytokines were higher in this group
compared to healthy controls (Table 4).
Discussion
This study shows that PIBF concentrations in body fluids
from pregnant women reflects certain pathological
events and is related to outcome of pregnacy. There is
ample evidence that PIBF is relevant for maintenance of
pregnacy and its actions are exerted through immuno-
logical mechanisms such as altered Th1/Th2 cytokine
balance w29, 33x. All patients during hospitalization due
to threatened miscarriage received gestagen therapy.
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Premature delivery of 5 (20%) patients in our study took
place after they were released from the clinics and
stopped gestagen therapy. Sanches-Ramos et al. w21x
published a randomized study that was conducted
among 1339 patients to establish the efficiency of pro-
gesterone therapy on prevention of premature deliveries.
They showed that gestagen (17-a hydroprogesteron and
other types of progesterone) lowered the risk of prema-
ture delivery and delivery of newborns with low birth
weight in patients with a history of early miscarriages and
threatened miscarriage in the current pregnancy. Similar
results found by Sfakianki and Norwitz w23x,
Szekeres-Bartho et al. w34x and Kalinka and Bartho w12x,
who determined the therapeutic effect of progesterone
through PIBF in patients with symptoms of threatened
miscarriage, noted that induction of production PIBF by
Dydrogesteron significantly reduces the frequency of
miscarriages. Similar conclusions were reached by other
authors, in agreement with results of our study w3, 7x.
We found significantly higher concentration of pro-
inflammatory cytokines in patients with threatened spon-
taneous abortion, in accord with studies conducted by
many authors w3, 7, 19, 36x. Most authors conclude that
IL10 has the key anti-inflammatory immune response w2,
5, 19x. Palfi et al. w16x did not find a difference between
healthy pregnant women and controls when the serum
ratio of Th1/Th2 cytokines was measured in patients with
habitual miscarriages, and suggested a crucial impact on
outcome of pregnancy by a ratio between proinflamma-
tory and anti-inflammatory cytokines. Sedlmayr w22x
found higher IL6 concentration produced by macro-
phages in decidual cells in patients with repeated mis-
carriages, in accord with our research. Similar results
were noted by other authors w9, 10x. These results are
different from Wolff et al. w37x and Baek w1x who noted
lower IL6 values in serum of patients with idiopathic mis-
carriages. TNFa belongs to the group of proinflammatory
cytokines and it inhibits placental differentiation and inva-
sion, laying down the extracellular matrix, hormone pro-
duction, deactivation of macrophages and inhibits the
production of cytokines in many tissues. These are actu-
ally pathophysiological mechanisms that lead to miscar-
riage w8, 15, 24x. Many authors noted a direct influence
of higher TNFa values on development of miscarriages
w2, 5, 14x. Interferon gamma belongs to the group of
proinflammatory cytokines which was the subject of
much research on immunological causes of miscarriages
w4x. Most authors found direct connection between high-
er serum and local concentration (fetomaternal units)
INFg in patients with miscarriages, which was found in
this study as well w5, 9, 11, 17, 27x. Contrary to our study,
some studies did not find an influence of higher serum
concentration of INFg on development of miscarriage
w16, 18x.
We conclude that (1) concentrations of PIBF in urine
and serum are significantly lower in pregnant women with
threatened miscarriage; (2) concentration of anti-inflam-
matory cytokine (IL10) in serum is significantly lower, and
concentration of proinflammatory cytokines (IL6, IFNg,
TNFa) is significantly higher in pregnant women with
symptoms of threatened miscarriage; (3) determination of
concentration PIBF in urine and in serum, as well as IL6,
IFNg, TNFa and IL10 cytokines in serum might be used
as a diagnostic and prognostic parameter of threatened
abortion.
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